Researchers concluded that the high - dose vaccine is safe, induces significantly higher antibody responses, and provides superior protection against laboratory - confirmed influenza illness compared to
standard dose among persons over 65 years of age.
Not exact matches
During the following season (2013 - 2014), when H1N1 viruses dominated and the
standard -
dose vaccine had better effectiveness than the previous season, the high -
dose vaccine was not significantly better at preventing deaths
among the Medicare patients studied.
But the Congolese government, worried that the virus could spread rapidly
among Kinshasa's 10 million residents, has decided to stretch the 1.7 million
doses it has received by giving people 0.1 milliliters of the vaccine each instead of the
standard 0.5 milliliters.
In the end, the hospitalization rate for respiratory illnesses
among high -
dose patients was 3.4 percent compared to 3.8 percent
among standard -
dose patients over the six months after vaccination.